JMX-2006

JMX-2006 is an orally bioavailable androgen receptor (AR) degrader developed by Nanjing Hengsheng Pharmaceutical for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It utilizes Proteolysis Targeting Chimera (PROTAC) technology to induce the ubiquitination and subsequent proteasomal degradation of the androgen receptor. By targeting the AR protein for destruction rather than simply inhibiting its activity, JMX-2006 is designed to overcome common resistance mechanisms such as AR overexpression and mutations that often render second-generation anti-androgens ineffective. The drug is currently undergoing early-phase clinical evaluation to assess its safety, pharmacokinetics, and preliminary efficacy in patients with advanced prostate cancer.